专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003059898A3 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF 审中-公开
公开(公告)号：WO2003059898A3
公开(公告)日：2003-07-24
申请号：PCT/US2003/000390
申请日：2003-01-08
申请人： EISAI CO. LTD. , AGOULNIK, Sergei , AKASAKA, Kozo , FANG, Frank , HARMANGE, Jean-Christophe , HAWKINS, Lynn , JIANG, Yimin , JOHANNES, Charles , LI, Xiang-Yi , MCGUINNESS, Pamela , MURPHY, Erin, A. , SCHILLER, Shawn , VERMEULEN, Mary , WU, Jiayi
发明人： AGOULNIK, Sergei , AKASAKA, Kozo , FANG, Frank , HARMANGE, Jean-Christophe , HAWKINS, Lynn , JIANG, Yimin , JOHANNES, Charles , LI, Xiang-Yi , MCGUINNESS, Pamela , MURPHY, Erin, A. , SCHILLER, Shawn , VERMEULEN, Mary , WU, Jiayi
IPC分类号： C07D303/36
摘要： The present invention provides compounds having formula (I) : wherein R 1 -R 6 , A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

2. 发明申请

WO2015184145A8 USE OF ERIBULIN AND POLY (ADP RIBOSE) POLYMERASE (PARP) INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：使用ERIBULIN和POLY（ADP RIBOSE）聚合酶（PARP）抑制剂作为治疗癌症的组合疗法
公开(公告)号：WO2015184145A8
公开(公告)日：2016-02-04
申请号：PCT/US2015032990
申请日：2015-05-28
申请人： EISAI R&D MAN CO LTD , COX DAVID , KREMER ALTON , MCGONIGLE SHARON , WU JIAYI
发明人： COX DAVID , KREMER ALTON , MCGONIGLE SHARON , WU JIAYI
IPC分类号： A01N43/58
CPC分类号： A61K31/357 , A61K31/519 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineoplastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin).
摘要翻译：本发明的特征在于在有需要的患者中治疗癌症的方法，其通过与一种或多种PARP抑制剂和任选的基于铂的抗肿瘤药物组合施用eribulin及其试剂盒。本发明部分基于以下观察结果：甲磺酸艾布林，PARP抑制剂（例如E7449）和任选的基于铂的抗肿瘤药物（例如卡铂）的组合显示出改善的（例如协同）抗肿瘤效果。因此，本发明的特征在于通过使用eribulin（例如，甲磺酸eribulin）和一种或多种PARP抑制剂（例如E7449或其药学上可接受的）的组合来预防和治疗癌症（例如，同源重组（HR））缺陷性癌症的方法其盐（例如，酒石酸盐），任选地与铂基抗肿瘤药物（例如卡铂）组合。

3. 发明申请

WO2015184145A1 USE OF ERIBULIN AND POLY (ADP RIBOSE) POLYMERASE (PARP) INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：使用ERIBULIN和POLY（ADP RIBOSE）聚合酶（PARP）抑制剂作为治疗癌症的组合疗法
公开(公告)号：WO2015184145A1
公开(公告)日：2015-12-03
申请号：PCT/US2015/032990
申请日：2015-05-28
申请人： EISAI R&D MANAGEMENT CO., LTD. , COX, David , KREMER, Alton , MCGONIGLE, Sharon , WU, Jiayi
发明人： COX, David , KREMER, Alton , MCGONIGLE, Sharon , WU, Jiayi
IPC分类号： A01N43/58
CPC分类号： A61K31/357 , A61K31/519 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP 10 inhibitor (e.g., E7449), and, optionally, a platinum-based antineoplastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer; see below) by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a 15 platinum-based antineoplastic drug (e.g., carboplatin).
摘要翻译：本发明的特征在于在有需要的患者中治疗癌症的方法，其通过与一种或多种PARP抑制剂和任选的基于铂的抗肿瘤药物组合施用eribulin及其试剂盒。本发明部分基于以下观察结果：甲磺酸艾美林，PARP 10抑制剂（例如E7449）和任选的基于铂的抗肿瘤药物（例如卡铂）的组合显示出改善的（例如协同）抗肿瘤效果。因此，本发明的特征在于通过使用eribulin（例如，甲磺酸eribulin）和一种或多种PARP抑制剂（例如E7449）的组合来预防和治疗癌症（例如，同源重组（HR）缺陷性癌症;参见下文）或其药学上可接受的盐（例如，酒石酸盐），任选地与15种基于铂的抗肿瘤药物（例如卡铂）组合。

4. 发明申请

WO2003059898A2 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF 审中-公开
标题翻译： EPONEMYCIN和EPOXOMICIN类似物及其用途
公开(公告)号：WO2003059898A2
公开(公告)日：2003-07-24
申请号：PCT/US2003/000390
申请日：2003-01-08
申请人： EISAI CO. LTD. , AGOULNIK, Sergei , AKASAKA, Kozo , FANG, Frank , HARMANGE, Jean-Christophe , HAWKINS, Lynn , JIANG, Yimin , JOHANNES, Charles , LI, Xiang-Yi , MCGUINNESS, Pamela , MURPHY, Erin , SCHILLER, Shawn , VERMEULEN, Mary , WU, Jiayi
发明人： AGOULNIK, Sergei , AKASAKA, Kozo , FANG, Frank , HARMANGE, Jean-Christophe , HAWKINS, Lynn , JIANG, Yimin , JOHANNES, Charles , LI, Xiang-Yi , MCGUINNESS, Pamela , MURPHY, Erin , SCHILLER, Shawn , VERMEULEN, Mary , WU, Jiayi
IPC分类号： C07D303/36
CPC分类号： C07D209/48 , A61K38/00 , C07D303/36 , C07D405/12 , C07D407/12 , C07F5/025 , C07F9/65502 , C07K5/06139
摘要： The present invention provides compounds having formula (I) : wherein R 1 -R 6 , A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.
摘要翻译：本发明提供具有式（I）的化合物：其中R 1 -R 6，A，J，D，E，G，Q，w，x，y和z如本文中所述的一般和类别和亚类所述，其药物组合物及其用于治疗癌症和/或炎症性疾病的方法，更一般地，作为蛋白酶体抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式